<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844297</url>
  </required_header>
  <id_info>
    <org_study_id>CACT1215</org_study_id>
    <nct_id>NCT01844297</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy</brief_title>
  <official_title>Efficacy and Safety of Tenofovir Disoproxil Fumarate Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy for ART-naive Chinese Patients With HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and effectiveness of the tenofovir disoproxil fumarate&#xD;
      (TDF) + lamivudine (3TC) + efavirenz (EFV) regimen in antiretroviral therapy (ART)-naive&#xD;
      Chinese HIV/AIDS patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, open-label, multi-centered clinical trial to assess the&#xD;
      virologic suppression and immune recovery rates as well as tolerability of the regimen&#xD;
      3TC+TDF+EFV in ARV-naive Chinese population.&#xD;
&#xD;
      500 eligible participants will be recruited to take the regimen If the patient fails to&#xD;
      tolerate EFV, it can be substituted by NVP when CD4 &lt; 250/μL, and by LPV/r when CD4 &gt; 250/uL.&#xD;
      If the patient fails to tolerate TDF, AZT will be an alternative, except when Hb &lt; 90/L or&#xD;
      neutrophil count &lt; 0.75×109/L. The participants will be followed up by months 0.5, 1, 2 ,3&#xD;
      and every 3 months subsequently for 2 years.&#xD;
&#xD;
      The efficacy of the regimen will be evaluated by comparison between different points along&#xD;
      the time line and previous regimens. The safety of the regimen will be assessed by monitoring&#xD;
      kidney function, bone density, cardiovascular profile, lipid profile, liver function etc as&#xD;
      well as other adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 96</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 40 Copies/mL at Week 96</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 count at Week 48</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 count at Week 96</measure>
    <time_frame>Baseline and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and laboratory abnormalities from baseline to week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and laboratory abnormalities from baseline to week 96</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>AIDS/HIV PROBLEM</condition>
  <arm_group>
    <arm_group_label>TDF+3TC+EFV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF+3TC+EFV</intervention_name>
    <arm_group_label>TDF+3TC+EFV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18-65 years of either gender&#xD;
&#xD;
          -  HIV-1 antibody seropositive detected by ELISA and confirmed by western blot&#xD;
&#xD;
          -  CD4 cell count &lt; 500/ul&#xD;
&#xD;
          -  Signed informed consent, with no condition that precludes follow-up for 2 years&#xD;
&#xD;
          -  No plan to move out of the area during the trial&#xD;
&#xD;
          -  antiretroviral therapy naive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients in acute phase of HIV infection&#xD;
&#xD;
          -  patients with ongoing opportunistic infection or AIDS-related malignancies; or with&#xD;
             opportunistic infection within previous 3 months and still unstable within 14 days&#xD;
             before inclusion&#xD;
&#xD;
          -  patients with the any of the following test results during screening for inclusion:&#xD;
&#xD;
               -  WBC count &lt; 2000/ul,&#xD;
&#xD;
               -  neutrophil count &lt; 1000/ul,&#xD;
&#xD;
               -  Hb &lt; 9g/dl,&#xD;
&#xD;
               -  platelet count &lt; 75000/ul,&#xD;
&#xD;
               -  serum creatinine &gt; 1.5 ULN,&#xD;
&#xD;
               -  transaminases or alkaline phosphatase &gt; 3 ULN,&#xD;
&#xD;
               -  total bilirubin &gt; 2 ULN,&#xD;
&#xD;
               -  serum creatinine kinase &gt; 2 ULN&#xD;
&#xD;
          -  CCr &lt; 60ml/min&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Intravenous drug user&#xD;
&#xD;
          -  Severe neuropathy or mental disorder&#xD;
&#xD;
          -  history of alcohol abuse and unable to withdrawal&#xD;
&#xD;
          -  Severe peptic ulcer disease&#xD;
&#xD;
          -  Non-Chinese nationality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tai sheng Li, MD</last_name>
    <phone>86-10-69155086</phone>
    <email>litsh@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Lv, MD</last_name>
      <phone>86-10-69155082</phone>
      <email>lvweipumch@163.com</email>
    </contact>
    <investigator>
      <last_name>Taisheng Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>August 24, 2012</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <last_update_submitted>April 26, 2013</last_update_submitted>
  <last_update_submitted_qc>April 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College</investigator_affiliation>
    <investigator_full_name>LI Taisheng</investigator_full_name>
    <investigator_title>director of the Department of Infectious Disease</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

